Rallybio Corporation RLYB on Tuesday shared results from its Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) ...

Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is the complement system—a group of proteins that ...

This Rare Disease Day, observed on Feb. 28 worldwide, the American Kidney Fund is committed to improving the understanding of rare kidney diseases by providing educational resources. An autoimmune ...

A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...

Harvard Medical School scientists have identified a key protein in the human immune system that drives inflammatory and autoimmune conditions when it turns against the body. The protein, Granzyme K, ...

In a recent study published in Molecular Psychiatry, researchers review the anti-inflammatory effects of ketamine in the peripheral and central nervous systems. To this end, all relevant articles were ...

"NM-8074 (Ruxoprubart) Sales Forecast"NM-8074 (ruxoprubart) sales market analysis provides in-depth insights into NM-8074 annual sales, market size, and growth forecast across the 7MM through 2034.